✦ LIBER ✦

Recent Developments in the Field of A2A and A3 Adenosine Receptor Antagonists

✍ Scribed by Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Andrea Bovero; Barbara Avitabile; Delia Preti; Francesca Fruttarolo; Romeo Romagnoli; Katia Varani; Pier Andrea Borea

Publisher: John Wiley and Sons
Year: 2003
Weight: 51 KB
Volume: 34
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200334242

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Discovery and Synthesis of Novel Ade

The Discovery and Synthesis of Novel Adenosine Receptor (A2A) Antagonists.

✍ Julius J. Matasi; John P. Caldwell; Jinsong Hao; Bernard Neustadt; Leyla Arik; C 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 21 KB

Comparative molecular field analysis (Co

Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists

✍ Pier Giovanni Baraldi; Pier Andrea Borea; Manuela Bergonzoni; Barbara Cacciari; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 2 views

Selective and potent antagonists for the A 2A adenosine receptors have been described recently. The most potent compounds have a triazolo-pyrimidine structure, whereas 8-styryl-xanthines usually possess lower affinity at the A 2A receptor. We have examined the quantitative structure activity relatio

A2A-selective adenosine receptor antagon

A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand

✍ Christa E. Müller; Roland Sauer; Yuris Maurinsh; Rosa Huertas; Friederike Fülle; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

A 2A adenosine receptor (AR) antagonists are promising new drugs for the treatment of Parkinson's disease. Further potential therapeutic indications for A 2A AR antagonists include dementias, ischemias, and pain. Potent, selective A 2A AR antagonists have been developed, but their generally low wate

Pyran template approach to the design of

Pyran template approach to the design of novel A3 adenosine receptor antagonists

✍ An-Hu Li; Xiao-duo Ji; Hak Sung Kim; Neli Melman; Kenneth A. Jacobson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 2 views

A 3 adenosine receptor antagonists have potential as anti-inflammatory, anti-asthmatic, and anti-ischemic agents. We previously reported the preparation of chemical libraries of 1,4-dihydropyridine (DHP) and pyridine derivatives and identification of members having high affinity at A 3 adenosine rec

ChemInform Abstract: Recent Advances in

ChemInform Abstract: Recent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide V1a and V2 Receptor Antagonists

✍ J. D. ALBRIGHT; P. S. CHAN 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

Potent antagonists for the human adenosi

Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity

✍ Maarten de Zwart; Roel C. Vollinga; Margot W. Beukers; Danielle F. Sleegers; Jac 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

A series of novel and known 5-substituted 7-amino-2-(2-furyl) [1,2,4]triazolo [1,5a][1,3,5]triazine derivatives were synthesized and tested for adenosine receptor antagonism in radioligand binding assays at all four adenosine receptor subtypes and for inhibition of the agonist-induced cyclic AMP res